Amendment to Schedule 13D Filing for Evommune, Inc.

This filing is an amendment to a previously filed Schedule 13D concerning Evommune, Inc. common stock. LSP 7 Cooperatieve U.A. has acquired 358,680 shares for $9,999,998.40 through a private placement that closed on February 17, 2026. This acquisition brings their total beneficial ownership to 5,288,313 shares, representing approximately 14.7% of the outstanding stock. The acquisition was funded by capital contributions from LSP 7's members. The filing also details a Registration Rights Agreement entered into on February 12, 2026, obligating the issuer to file a registration statement for the resale of these shares. The reporting person, LSP 7 Cooperatieve U.A., has shared voting and dispositive power over these shares.